Avalo Therapeutics (AVTX) Free Cash Flow (2014 - 2026)

Avalo Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at -$17.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 87.16% year-over-year to -$17.7 million; the trailing twelve-month figure through Mar 2026 stood at -$59.7 million (down 14.21% YoY), and the FY2025 full-year result was -$51.5 million, down 4.98% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$17.7 million, down from -$14.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $5.7 million in Q3 2022, with the low at -$17.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$10.3 million across 5 years, with a median of -$11.4 million in 2025.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 134.74% — and 2024, when it tumbled 443.89%.
• Avalo Therapeutics' Free Cash Flow stood at -$3.8 million in 2022, then increased by 28.06% to -$2.8 million in 2023, then plunged by 443.89% to -$15.0 million in 2024, then climbed by 5.03% to -$14.3 million in 2025, then fell by 23.88% to -$17.7 million in 2026.
• The last three Free Cash Flow figures came in at -$17.7 million (Q1 2026), -$14.3 million (Q4 2025), and -$16.4 million (Q3 2025), per Business Quant data.